Company Update - Cumberland Pharmaceuticals Inc. will release its third quarter 2024 financial results and provide a company update on November 7, 2024, after market close [1] - A conference call is scheduled for November 7 at 4:30 p.m. Eastern Time to discuss the results, with registration available online [1][2] Product Portfolio - Cumberland Pharmaceuticals focuses on developing, acquiring, and commercializing unique products for hospital acute care, gastroenterology, and oncology markets [3] - The company's FDA-approved products include Acetadote®, Caldolor®, Kristalose®, Sancuso®, Vaprisol®, and Vibativ®, which address various medical conditions such as acetaminophen poisoning, pain and fever, constipation, chemotherapy-induced nausea, hyponatremia, and serious bacterial infections [3] Clinical Programs - The company is conducting Phase II clinical programs for its ifetroban product candidate, targeting conditions such as Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis [4]

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2024 Results Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon. And welcome to Cumberland Pharmaceuticals Second Quarter 2024 Financial Report and Company Update. This call is being recorded at the company's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or Othe ...

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 NASHVILLE, TENNESSEE (Tuesday, August 6, 2024) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: • $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024. • Adjuste ...

NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024. Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period ...

A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e. A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting https://edge.media-server.com/mmc/p/h9bx4zn8. The company's portfolio of FDA-approved brands includes: The company also has a series of Phase II clinical programs underway evaluating its if ...

| --- | --- | --- | --- | --- | --- | --- | |-------|--------|-------|-------|-------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 00 | 0 (80) | | | CUMBERLAND® P H A R M A C E U T I C A L S | | | | | | | | Corporate Presentation | | | | | | | | Nasdaq CPIX | | | Nation's Nashville is a diverse hankh care has with growth sectors Including ambulatory and outpatient surgery, long-term caro. Mission & Stra ...

Start Time: 15:30 January 1, 0000 3:59 PM ET Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2024 Earnings Conference Call May 07, 2024, 15:30 PM ET Company Participants A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Molly Aggas - Account Supervisor, Dalton Agency Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals First Quarter 2024 Financial Report and Company Update. This call is being recorded at Cumberland's request and will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Cumberland Pharmaceuticals Inc. (Exact Name of Registrant as Specified In Its Charter) Tennessee 62-1765329 (State or Other Jurisdiction of Incorporation o ...

Cumberland Pharmaceuticals Reports First Quarter 2024 ® About Kristalose (lactulose) Oral Solution ® About Sancuso (granisetron) Transdermal System Sancuso is the only skin patch approved by the U.S. Food and Drug Administration for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the SANCUSO patch slowly and continuously releases the medicine contained in the a ...